Pediatrix Medical Group Inc

Pediatrix Medical Group Inc(MD)股票分析

$29.290

-0.258 (-0.88%)收盤時

Loading chart…
最高
29.700
開盤
29.410
成交量加權均價
29.32
成交量
574.87K
市值
607.54M
最低
28.985
成交金額
16.86M
企業價值/稅息折舊攤銷前利潤(TTM)
9.34

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

AI 分析 of Pediatrix Medical Group Inc (MD)

持有

Pediatrix Medical Group Inc is currently a hold. The stock is trading at $29.29, which is above the recent analyst target of $28 from Jefferies. The RSI is at 78.905, indicating that the stock is overbought, which may lead to a price correction. Despite a strong year-to-date change of +37.58% and a forward P/E of 9.2937, the recent downgrade and potential earnings growth cap present risks.

分析師評級(14)

-19.77% 下跌空間
持有
3 買進
10 持有
1 賣出
目前: 29.29
最低
23.00
平均
23.50
最高
24.00

Jefferies

2026-08-19

目標價

$28

持有

UBS

2026-08-06

目標價

$28

中性

Deutsche Bank

2026-08-05

目標價

$25

持有

UBS

2026-05-12

目標價

$25

中性

Mizuho

2026-05-08

目標價

$24

中性

估值指標

Pediatrix Medical Group Inc(MD)目前預期本益比為 9.29,5 年平均預期本益比為 9.33。

預期本益比

合理
5 年均值 P/E
9.33
目前P/E
9.29
高估
11.60
低估
7.05

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
8.01
目前EV/EBITDA
9.34
高估
9.63
低估
6.40

預期股價營收比

高估
5 年均值 P/S
0.71
目前P/S
1.20
高估
0.96
低估
0.47

Alphio AI 對 MD 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MD

$14.32

情境價格

基

基準

基準 · 50%MD

$11.56

情境價格

悲

悲觀

悲觀 · 25%MD

$9.40

情境價格

持有 MD 的大戶

D

Dana Investment Advisors Inc

+ 持有MD

+2.89%

3個月報酬率

A

Applied Finance Advisors, LLC

+ 持有MD

-8.02%

3個月報酬率

事件時間軸

2026-08-04 (ET)

06:30:00

Pediatrix Medical Sees 2026 Adjusted EBITDA of $280M-$300M

06:30:00

Company Reports Q2 Revenue of $487.8M, Exceeds Expectations

2026-07-15 (ET)

07:00:00

Pediatrix Medical Group Confirms Stable Q2 2026 Business Trends

2026-05-05 (ET)

06:20:00

Pediatrix Medical Reaffirms FY26 Adjusted EBITDA View of $280M-$300M

06:10:00

Pediatrix Medical Group Q1 Revenue Reaches $476M

資訊

MD 常見問題 —— 由 Alphio AI 解答

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice. It operates in the Healthcare sector (SERVICES-HOSPITALS industry).

Pediatrix Medical Group Inc is currently a hold. The stock is trading at $29.29, which is above the recent analyst target of $28 from Jefferies. The RSI is at 78.905, indicating that the stock is overbought, which may lead to a price correction. Despite a strong year-to-date change of +37.58% and a forward P/E of 9.2937, the recent downgrade and potential earnings growth cap present risks.

14 analysts cover MD: 3 rate it Buy, 10 Hold and 1 Sell. The average price target is 23.50.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易